Drug Details

General Information of the Drug (ID: DR2168)
Name
Pioglitazone
Synonyms
Pioglitazone; 111025-46-8; Actos; 105355-27-9; Pioglitazona; Pioglitazonum; Glustin; Pioglitazonum [INN-Latin]; Pioglitazona [INN-Spanish]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; Zactos; Duetact; U 72107; AD-4833; Pioglitazone-d4; CHEBI:8228; Pioglitazone (Actos); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; Actos (TN); 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; U-72107; 2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-; MFCD00865504; 105390-47-4; Pioglitazone [BAN:INN]; Pioglitazone [INN:BAN]; Piozone; Pioglu; 5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione; [( inverted exclamation markA)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochlorid; pioglitazone (INN); 1134163-31-7; HSDB 7322; U-72107E; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4-thiazolidinedione; SR-01000763737; Pioglitazone-[d4]; HS-0047; Spectrum_001623; Spectrum2_001679; Spectrum3_001002; Spectrum4_001130; Spectrum5_001480; Spectrum5_002067; SCHEMBL4121; BSPBio_002723; KBioGR_001619; KBioSS_002103; MLS006011848; SPBio_001897; GTPL2694; DTXSID3037129; KBio2_002103; KBio2_004671; KBio2_007239; KBio3_001943; HMS2089H14; HMS3651D09; HMS3712E16; HMS3884L10; Pharmakon1600-01504401; ACT02635; BCP26474; BBL029068; BDBM50103521; NSC758876; s2590; STL309607; STL373406; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; AKOS015894953; AKOS022109420; AC-1021; CCG-220107; CS-1700; DB01132; MCULE-2346786634; NSC-758876; SB17323; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, (+-)-; NCGC00163128-01; NCGC00163128-02; NCGC00163128-03; NCGC00163128-04; NCGC00163128-05; NCGC00163128-06; NCGC00163128-07; AK-56326; HY-13956; SMR002204015; SY017473; SBI-0206791.P001; AB0004710; DB-027350; FT-0601906; FT-0645030; SW197561-3; C07675; D08378; J10289; K-0703; AB00698454-10; AB00698454_11; AB00698454_12; AB00698454_13; 355P279; A801204; Q417765; J-002506; J-516181; SR-01000763737-5; BRD-A48430263-003-02-4; BRD-A48430263-003-06-5; 5-[4-[2-(5-ethyl-2-pyridyl) ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(5-ethyl-2-pyridyl)eth-oxy]benzyl]-2,4-thiazolidinedione; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4thiazolidinedione; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)-thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl-2,4-thiazolidinedione; 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy] phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI); 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, (+/-)-; 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-4-hydroxy-1,3-thiazol-2(5H)-one
    Click to Show/Hide
Molecular Type
Small molecule
Disease Acute diabete complication [ICD-11: 5A2Y] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C19H20N2O3S
PubChem CID
4829
Canonical SMILES
CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
InChI
1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)
InChIKey
HYAFETHFCAUJAY-UHFFFAOYSA-N
CAS Number
CAS 111025-46-8
ChEBI ID
CHEBI:8228
TTD Drug ID
D03OFF
DrugBank ID
DB01132
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          D-cycloserine      Streptomyces garyphalus     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Orofacial neuropathic pain mouse model was used in this study.
                    Experimental
                    Result(s)		 The DCS/PIO combination not only attenuated orofacial neuropathic pain and anxiety-related behaviors associated with trigeminal nerve injury, but it also improved mitochondrial bioenergetics.
          Metformin      Galega officinalis     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 Metformin/pioglitazone/exenatide in patients with newly diagnosed T2DM is more effective and results in fewer hypoglycaemic events than sequential add-on therapy with metformin, sulfonylurea and then basal insulin.
Target and Pathway
Target(s) PPAR-gamma (PPARG)  Molecule Info  [4]
KEGG Pathway PPAR signaling pathway Click to Show/Hide
2 AMPK signaling pathway
3 Osteoclast differentiation
4 Huntington's disease
5 Pathways in cancer
6 Transcriptional misregulation in cancer
7 Thyroid cancer
NetPath Pathway IL1 Signaling Pathway Click to Show/Hide
2 TGF_beta_Receptor Signaling Pathway
3 Leptin Signaling Pathway
Panther Pathway CCKR signaling map ST Click to Show/Hide
Pathway Interaction Database Noncanonical Wnt signaling pathway Click to Show/Hide
2 Calcineurin-regulated NFAT-dependent transcription in lymphocytes
3 Signaling events mediated by HDAC Class I
4 RXR and RAR heterodimerization with other nuclear receptor
5 Regulation of retinoblastoma protein
Reactome PPARA activates gene expression Click to Show/Hide
2 Transcriptional regulation of white adipocyte differentiation
3 Nuclear Receptor transcription pathway
WikiPathways Wnt Signaling Pathway Netpath Click to Show/Hide
2 Nuclear Receptors in Lipid Metabolism and Toxicity
3 Differentiation of white and brown adipocyte
4 Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
5 Transcriptional Regulation of White Adipocyte Differentiation
6 Adipogenesis
7 SREBP signalling
8 Nuclear Receptors
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2694).
Reference 2 Combination Drug Therapy of Pioglitazone and D-cycloserine Attenuates Chronic Orofacial Neuropathic Pain and Anxiety by Improving Mitochondrial Function Following Trigeminal Nerve Injury. Clin J Pain. 2018 Feb;34(2):168-177.
Reference 3 Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab. 2015 Mar;17(3):268-75.
Reference 4 Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
 Download Picture         KEGG Link